lactate dehydrogenase

(R)-GNE-140 (GNE-140) is an effective LDHA LDHB inhibitor (IC50s: 3 5 nM) and is 18-fold more potent than S enantiomer.

Galloflavin is a lactate dehydrogenase inhibitor that inhibits the activity of lactate dehydrogenase. Galloflavin inhibits both human LDH isoforms (type A and type B) by preferentially binding to the free enzyme without competing with substrates or cofactors, with Ki values ​​calculated by pyruvate of 5.46 μM (LDH-A) and 15.06 μM (LDH-B).

L-Lactate dehydrogenase (LAD) is an oxidoreductase enzyme in the anaerobic metabolic pathway and the gluconeogenic pathway, and is found in a wide range of tissues in the body.

D-Lactate dehydrogenase (D-LDH), an oxidoreductase, catalyzes the oxidation of D-lactate to pyruvate leveraging NAD+ or NADP+ as acceptors and acting on the donor CH-OH group. Predominantly found in bacteria and fungi, it is frequently utilized in biochemical research [1].

FX-11 (LDHA Inhibitor FX11) is A potent, selective and competitive specific inhibitor of lactate dehydrogenase A (LDHA) with a Ki of 8 μM. FX-11 can activate PKM2 (pyruvate kinase M2). FX-11 can reduce ATP levels, induce oxidative stress and ROS production, and cause cell death. FX-11 appeared antitumor activity during xenotransplantation of lymphoma and pancreatic cancer.

(L)-Sodium lactate (Sodium L-Lactate) is produced from pyruvate by the enzyme Lactate Dehydrogenase. Lactate production occurs during anaerobic glycolysis or in proliferatively active cells. L-Lactic Acid occurs in small quantities in the blood and muscle fluid of man and animals. The lactic acid concentration increases in muscle and blood after vigorous activity. L-Lactic acid is also present in liver, kidney, thymus gland, human amniotic fluid, and other organs and body fluids.

LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) is a potent non-competitive lactate dehydrogenase (LDHA) inhibitor with an IC50 value of 145.2 nM.LDHA-IN-3 is a selenobenzene compound that can be used in cancer research.

Sodium 2-hydroxybutanoate (alpha-hydroxybutyrate) is formed as a by-product of the formation of alpha-ketobutyrate via a reaction catalyzed by lactate dehydrogenase (LDH) or alpha-hydroxybutyrate dehydrogenase (alphaHBDH).

(S)-2-Hydroxy-3-phenylpropanoic acid (L-(−)-3-Phenyllactic acid) is a chiral aromatic compound involved in phenylalanine metabolism. It is likely produced from phenylpyruvate via lactate dehydrogenase. The D-form is derived from bacterial sources, while the L-form is endogenous. Phenyllactate levels are normally very low in blood or urine, but high levels indicate phenylketonuria (PKU) and hyperphenylalaninemia (HPA). PKU is due to a deficiency of phenylalanine hydroxylase (PAH), causing phenylalanine to convert to phenylpyruvic acid rather than tyrosine.

Nifurtimox (BAY-A-2502) is an antiprotozoal agent (IC50s = 9.91, 12.28, and 10.44 μM against Taluahuén, LQ, and Brener strains of T. cruzi- epimastigotes, respectively).

4-(Dimethylamino)phenol enhances extracellular lactate dehydrogenase (LDH) levels without significant effects on gluconeogenesis. Only when the membrane becomes permeable to LDH does 4-(Dimethylamino)phenol reduce ATP content.

Isomalt (Palatinitol) is a mixture of 1,6-mannitol glucopyranoside and 1,6-sorbitol glucopyranoside

LDHA-IN-8, a small molecule inhibitor of lactate dehydrogenase A (LDHA), inhibits the proliferation of pancreatic and lung cancer cells by inhibiting the activity of LDHA-catalyzed pyruvate in a dose-dependent manner (EC 50=14.54μM), decreasing the intracellular lactate content and increasing the intracellular reactive oxygen species (ROS) levels.

LDH-IN-1 is a pyrazole-based human lactate dehydrogenase (LDH) inhibitor(IC50s of 32 and 27 nM for LDHA and LDHB, respectively).

GSK2837808A is a potent and selective inhibitor of lactate dehydrogenase A (LDHA) with IC50 values of 1.9 nM for LDHA and 14 nM for LDHB.

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

PfDHODH-IN-1, an analogue of the active Leflunomide metabolite, exhibits antimalarial activity.

GNE-140 is a potent inhibitor of lactate dehydrogenase A (LDHA). GNE-140 is a racemate mixture of (R)-GNE-140 and (S)-GNE-140.

Thevetiaflavone (2-Genistein-5-methyl ether) is a natural flavonoid from Wikstroemia indica that inhibits the leakage of lactate dehydrogenase from the cytoplasm and increases cell viability.

iNOs-IN-5 (Compound BN-4) is an inhibitor of iNOS with an IC50 value of 0.1707 μM, effectively reducing NO expression in RAW264.7 cells stimulated by LPS (HT-D1056). It further diminishes the expression of ROS and lactate dehydrogenase induced by hypoxic injury, displaying anti-necrotic and anti-apoptotic properties. In an SD rat model, iNOs-IN-5 exhibits neuroprotective effects against cerebral ischemia and is capable of crossing the blood-brain barrier.

LDH-IN-3 (compound E38) is an inhibitor of lactate dehydrogenase (LDH) and a potential protective agent against ischemic neuronal damage in the eyes and brain. It functions through the HO-1 SIRT1 pathway.

6,6′-Trehalose dioleate (6,6′-TDO) is a glycolipid extensively used for in vivo and in vitro mRNA delivery. This compound effectively encapsulates mRNA encoding hemagglutinin A (HA) from influenza A virus for use within lipid nanoparticles (LNPs), enhancing the secretion of Ifn-γ, Il-2, and Tnf-α from isolated murine spleen cells. When administered via intramuscular injection in mice, LNPs containing 6,6′-TDO predominantly accumulate in the liver and spleen. Unlike LNP formulations without 6,6′-TDO, those containing 6,6′-TDO do not reduce serum levels of blood urea nitrogen (BUN) or elevate levels of lactate dehydrogenase (LDH), troponin I, alanine aminotransferase (ALT), or aspartate aminotransferase (AST). Additionally, these LNPs enhance the serum titers of IgG1 and IgG2a antibodies in mice.

BMS-191095 hydrochloride is a mitochondrial KATP channel opener. It offers cardioprotective benefits without causing vasodilation or impacting electrophysiology. Its protective mechanisms include prolonging myocardial contraction during ischemia, enhancing contractile function post-reperfusion, and reducing lactate dehydrogenase (LDH) release.

GNE-140 racemic is a potent lactate dehydrogenase (LDHA) inhibitor.